511 related articles for article (PubMed ID: 29462502)
1. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
2. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
4. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Samaan MA; Arkir Z; Ahmad T; Irving PM
Expert Opin Biol Ther; 2018 Dec; 18(12):1271-1279. PubMed ID: 30339466
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology.
Papamichael K; Cheifetz AS
Curr Opin Rheumatol; 2020 Jul; 32(4):371-379. PubMed ID: 32412995
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Papamichael K; Cheifetz AS
Curr Opin Gastroenterol; 2019 Jul; 35(4):302-310. PubMed ID: 30973355
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.
Lega S; Bramuzzo M; Dubinsky MC
Curr Med Chem; 2018; 25(24):2840-2854. PubMed ID: 28901267
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease.
McNeill RP; Barclay ML
Curr Opin Pharmacol; 2020 Dec; 55():41-46. PubMed ID: 33120169
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
[No Abstract] [Full Text] [Related]
10. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
[TBL] [Abstract][Full Text] [Related]
11. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
Franca R; Curci D; Lucafò M; Decorti G; Stocco G
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
[No Abstract] [Full Text] [Related]
13. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
14. Drug monitoring of biologics in inflammatory bowel disease.
Eser A; Primas C; Reinisch W
Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
[TBL] [Abstract][Full Text] [Related]
15. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
17. Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases.
Papamichael K; Stocco G; Ruiz Del Agua A
Ther Drug Monit; 2023 Oct; 45(5):579-590. PubMed ID: 37012629
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
Guidi L; Pugliese D; Panici Tonucci T; Berrino A; Tolusso B; Basile M; Cantoro L; Balestrieri P; Civitelli F; Bertani L; Marzo M; Felice C; Gremese E; Costa F; Viola F; Cicala M; Kohn A; Gasbarrini A; Rapaccini GL; Ruggeri M; Armuzzi A
J Crohns Colitis; 2018 Aug; 12(9):1079-1088. PubMed ID: 29860436
[TBL] [Abstract][Full Text] [Related]
20. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
